Form 4 for RGNX REGENXBIO Inc.
Accepted 2021-09-15 00:00:00 ET · period of report 2021-09-13 · accession 0001562180-21-005947 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-09-15 | 2021-09-13+ | RGNX | Mills Kenneth T. | Pres, CEO, Dir | M - OptEx | $3.62 | +38.0K | 314.1K | +14% | +$137.5K |
| DM | 2021-09-15 | 2021-09-13+ | RGNX | Mills Kenneth T. | Pres, CEO, Dir | S - Sale+OE | $44.71 | -38.0K | 281.0K | -12% | -$1.70M |
| DM | 2021-09-15 | 2021-09-13+ | RGNX | Mills Kenneth T. | Pres, CEO, Dir | M - OptEx | $0.00 | -38.0K | 37.8K | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-09-14 | M | A | 1,854 | $0.85 | 315,984 | D | — | — | |
| 2 | Common | Common Stock | 2021-09-14 | S | D | 35,000 | $45.11 | 280,984 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $45.00 to $45.55. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 3 | Common | Common Stock | 2021-09-13 | M | A | 3,000 | $3.76 | 283,984 | D | — | — | |
| 4 | Common | Common Stock | 2021-09-13 | S | D | 3,000 | $40.02 | 280,984 | D | — | — | |
| 5 | Common | Common Stock | 2021-09-14 | M | A | 33,146 | $3.76 | 314,130 | D | — | — | |
| 6 | Derivative | Employee Stock Option (Right to Buy) | 2021-09-14 | M | D | 33,146 | $0.00 | 232,854 | D | $3.76 · — to 2025-05-18 | 33,146 Common Stock | (F3) The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. |
| 7 | Derivative | Employee Stock Option (Right to Buy) | 2021-09-13 | M | D | 3,000 | $0.00 | 266,000 | D | $3.76 · — to 2025-05-18 | 3,000 Common Stock | (F3) The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. |
| 8 | Derivative | Employee Stock Option (Right to Buy) | 2021-09-14 | M | D | 1,854 | $0.00 | 37,816 | D | $0.85 · — to 2024-09-23 | 1,854 Common Stock | (F4) The previously granted option, representing a right to purchase a total of 708,200 shares, became exercisable as follows: 474,490 of the shares subject to the option are initial shares ("Initial Shares") and 233,710 of the shares subject to the option are contingent shares ("Contingent Shares"). 120,394 of the Initial Shares vested on September 17, 2014, 88,524 of the Initial Shares vested on September 17, 2015 and an additional 7,377 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. |